COVID-19: Vaccines and Therapeutics

The Food and Drug Administration said that Moderna can add up to 50% more doses per vial of its COVID-19 vaccine. Moderna had been shipping 10-dose vials; the FDA’s change will enable shipments to contain up to 15 doses per vial. 
The Department of Health and Human Services launched a nationwide network of trusted voices to encourage vaccinations and increase vaccine confidence. 
The Pfizer-BioNTech COVID-19 vaccine was well tolerated and demonstrated 100% efficacy and robust antibody responses in a phase 3 clinical trial in 2,260 children aged 12-15, the vaccine’s makers announced. 
As part of AHA’s Joining Hands for Greater Impact series, we talk to Atrium Health, American Airlines and Charlotte Douglas International Airport representatives about how they came together to “get shots in arms” in Charlotte, N.C. 
The Pfizer and Moderna COVID-19 vaccines reduced the risk of both asymptomatic and symptomatic SARS-CoV-2 infection by 90% at least two weeks after the second dose and by 80% at least two weeks after the first dose in a study of 3,950 vaccinated health care and other essential workers, the Centers…
AHA releases an infographic with storage requirements for the three FDA-authorized COVID-19 vaccines.
As more vaccine supplies become available and more jurisdictions expand priority categories or do away with them altogether, hospitals and health systems continue to work overtime to serve as access points.
Throughout the pandemic, innovative partnerships have helped hospitals and health systems ensure ongoing care for patients, health care workers and their communities. 
AstraZeneca revised its data on its COVID-19 vaccine candidate, stating that its AZD1222 vaccine showed a 76% efficacy in preventing symptomatic COVID-19.